Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A primary care physician is evaluating a 71-year-old female during an annual wellness examination. The patient's past medical history is significant for postmenopausal osteoporosis. She was diagnosed 5 years ago after a screening dual-energy x-ray absorptiometry (DEXA) scan showed a femoral neck T-score of -2.8. Following the diagnosis, she began therapy with oral risedronate, which she has taken consistently without any gastrointestinal side effects. She has no history of clinical or radiographic fractures. A DEXA scan completed 3 days ago reports a current femoral neck T-score of -2.1. Her daily routine includes walking two miles, and she takes over-the-counter cholecalciferol and calcium carbonate. Renal function and serum calcium are within normal limits. She inquires about her future medication plan. Which of the following is the most appropriate next step in management?

  1. Discontinue risedronate and reassess bone mineral density in 2 to 3 yearsAnswer
  2. B
    Continue oral risedronate for an additional 5 years
  3. C
    Discontinue risedronate and initiate daily subcutaneous teriparatide
  4. D
    Transition therapy to an annual intravenous zoledronic acid infusion
  5. E
    Obtain serum C-terminal telopeptide levels to determine the need for ongoing therapy

Answer

The most appropriate management is to discontinue risedronate and initiate a bisphosphonate holiday, with plans to reassess bone mineral density in 2 to 3 years.
This patient has completed a standard 5-year course of oral bisphosphonates and has achieved a stable, improved bone mineral density (T-score > -2.5) without sustaining any fragility fractures. Because bisphosphonates bind tightly to hydroxyapatite crystals in the bone matrix, they continue to inhibit osteoclast-mediated bone resorption long after the drug is stopped. Clinical guidelines recommend a 'bisphosphonate holiday' (temporarily discontinuing the drug for 2-3 years) for patients with low-to-moderate fracture risk. This strategy minimizes the risk of long-term complications, specifically atypical subtrochanteric/diaphyseal femoral fractures and osteonecrosis of the jaw, while maintaining adequate bone strength.

Step-by-Step Solution

1
Evaluate the patient's current fracture risk and response to 5 years of oral bisphosphonate therapy.
The patient has no history of fragility fractures, and her T-score has improved from -2.8 to -2.1, placing her in a low-to-moderate fracture risk category.
Determining the patient's current risk level is mandatory to decide whether to continue, stop, or change osteoporosis medication.
2
Apply clinical guidelines for long-term bisphosphonate use.
For low-to-moderate risk patients completing 5 years of oral therapy, a drug holiday is indicated.
Bisphosphonates incorporate into the bone matrix, providing residual anti-resorptive effects for years after discontinuation. A drug holiday minimizes the risk of rare but severe complications associated with prolonged use.

Key Concept

Patients who have completed 5 years of oral bisphosphonate therapy, have no history of fragility fractures, and have a current T-score greater than -2.5 should be offered a bisphosphonate holiday to reduce the risk of atypical femoral fractures and osteonecrosis of the jaw.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic